Business Description
Adlai Nortye Ltd
ISIN : US00704R1095
Share Class Description:
ANL: ADRDescription
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.
Financial Strength
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 3.12 | |||||
Equity-to-Asset | 0.61 | |||||
Debt-to-Equity | 0.4 | |||||
Debt-to-EBITDA | -0.41 | |||||
Piotroski F-Score | N/A/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History |
---|
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 39.22 | |||||
9-Day RSI | 23.19 | |||||
14-Day RSI | 23.7 | |||||
6-1 Month Momentum % | 44.89 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 2.01 | |||||
Quick Ratio | 2.01 | |||||
Cash Ratio | 1.96 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History |
---|
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
FCF Margin % | -368.16 | |||||
ROA % | -93.13 | |||||
ROIC % | -12.46 | |||||
ROC (Joel Greenblatt) % | -1583.05 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 10.55 | |||||
PB Ratio | 1.7 | |||||
Price-to-Tangible-Book | 1.7 | |||||
EV-to-EBIT | -0.85 | |||||
EV-to-EBITDA | -0.86 | |||||
EV-to-Revenue | 13.25 | |||||
EV-to-FCF | -3.6 | |||||
Price-to-Net-Current-Asset-Value | 2.66 | |||||
Price-to-Net-Cash | 2.83 | |||||
Earnings Yield (Greenblatt) % | -117.65 | |||||
FCF Yield % | -13.67 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ANL
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Adlai Nortye Ltd Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | 5 | ||
EPS (TTM) ($) | -2.125 | ||
Beta | 0 | ||
Volatility % | 0 | ||
14-Day RSI | 23.7 | ||
14-Day ATR ($) | 0.872197 | ||
20-Day SMA ($) | 5.212285 | ||
12-1 Month Momentum % | 0 | ||
52-Week Range ($) | 3.21 - 19.2999 | ||
Shares Outstanding (Mil) | 36.9 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 9999 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Adlai Nortye Ltd Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Adlai Nortye Ltd Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
Adlai Nortye Ltd Frequently Asked Questions
What is Adlai Nortye Ltd(ANL)'s stock price today?
The current price of ANL is $3.65. The 52 week high of ANL is $19.30 and 52 week low is $3.21.
When is next earnings date of Adlai Nortye Ltd(ANL)?
The next earnings date of Adlai Nortye Ltd(ANL) is 2024-07-04 Est..
Does Adlai Nortye Ltd(ANL) pay dividends? If so, how much?
Adlai Nortye Ltd(ANL) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |